TWST as reported
Twist Bioscience Corporation reported $432M of revenue over the trailing twelve months, +19% on the year before. 10 reported series are charted on this page, each one as filed.
$432M
Revenue, trailing twelve months · to Q3 2026 · +19% against the twelve months before
- Net Income
- −$137M
Net Income · +60% year on year · trailing twelve months to Q3 2026
- Free Cash Flow
- −$93M
Free Cash Flow · +36% year on year · trailing twelve months to Q3 2026
- Op Margin
- −34%
Op Margin · trailing twelve months to Q3 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $432M | +19% | Q3 2026 |
| Net Income | −$137M | +60% | Q3 2026 |
| EPS | −$2.22 | +53% | Q3 2026 |
| Gross Margin | 52% | n/a | Q3 2026 |
| Op Margin | −34% | n/a | Q3 2026 |
| Net Margin | −32% | n/a | Q3 2026 |
| ROE | −20% | n/a | Q3 2026 |
| ROA | −14% | n/a | Q3 2026 |
| ROIC | −139% | n/a | Q4 2021 · 19 quarters behind |
| Free Cash Flow | −$93M | +36% | Q3 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Twist Bioscience Corporation (TWST) - Revenue & ProfitRevenue & ProfitTwist Bioscience Corporation (TWST)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #4 of 29 by Smart Score